Optic nerve repair could treat glaucoma:
This article was originally published in Clinica
Mice treated with Boston Life Sciences' central nervous system growth factor Axogenesis Factor 1 (AF1) have re-grown severed axons within the optic nerve, suggesting that AF1 could be used to treat blindness caused by glaucoma. Degenerative injury to the optic nerve destroys the vision of glaucoma sufferers. This is the first time that injection of a single nerve growth factor has resulted in optic nerve regeneration, says Boston Life Sciences. The company's chief scientific officer, Dr Marc Lanser said, "These exciting data suggest that AF1 has the potential to be a totally novel approach to the treatment of glaucoma."
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.